Zanidatamab (NCT05035836)

Name: Zanidatamab trial for Breast Cancer (NCT05035836)
Uploaded: 2026-10-31T22:44:05.053Z
Duration: 1 min 16 s
Description: Zanidatamab trial for Breast Cancer (NCT05035836). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT05035836.

A Phase 2 Single-Arm Open-Label Pilot Trial Evaluating Zanidatamab (ZW25) in Patients With Early Stage HER2/Neu Positive (HER2+) Breast Cancer (BC): a one-minute explainerNCT050358361 min

Zanidatamab trial for Breast Cancer (NCT05035836). This is a short film with English narration. The transcript is on this page, and the written brief is separate.

What the film says

Read the transcript

This trial is for women older than 18 with untreated HER2-positive breast cancer measuring over one to three centimeters, without lymph-node or distant spread. Surgery must be planned.

The idea: zanidatamab binds two sites on HER2 to block growth signaling and recruit immune attack. It is infused every two weeks for up to six doses. Hormone-receptor-positive tumors also receive tamoxifen or letrozole. Researchers examine surgical tissue for remaining cancer and monitor side effects.

This phase 2 study plans 20 patients. Vicente Valero leads at MD Anderson in Houston, the sole recruiting US site.

Public record; not medical advice.

Read the full brief →

Already in a trial?

It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.

Organize my trial

7-day free trial, then $9 a month. Cancel anytime.